Connect with us

Health

Endometrial cancer patients see new hope as FDA approves 'transforming' immunotherapy drug

Published

on

Endometrial cancer patients see new hope as FDA approves 'transforming' immunotherapy drug

Join Fox News for access to this content

Plus special access to select articles and other premium content with your account – free of charge.

By entering your email and pushing continue, you are agreeing to Fox News’ Terms of Use and Privacy Policy, which includes our Notice of Financial Incentive.

Please enter a valid email address.

Having trouble? Click here.

The U.S. Food and Drug Administration (FDA) has approved a new drug for certain adult patients with endometrial cancer.

Jemperli (dostarlimab-gxly) — made by British pharmaceutical company GSK — is intended for people with primary advanced or recurrent forms of the cancer, according to the FDA’s Aug. 1 announcement.

Advertisement

It is an immunotherapy-based drug, which means it leverages the body’s immune system to attack cancer cells.

SOME TAMPON PRODUCTS FOUND TO CONTAIN TOXIC METALS IN FIRST-TIME STUDY: ‘HARMFUL INGREDIENTS’

In clinical trials, Jemperli showed an improved progression-free survival and overall survival for all patients, according to Dr. Brian Slomovitz, director of gynecologic oncology and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Florida.

“This class of drugs has been used in the second-line setting,” Slomovitz said — meaning they were only used if a first-line (primary) treatment was not effective or had intolerable side effects.

The FDA has approved a new drug for certain adult patients with endometrial cancer. (iStock)

Advertisement

“Moving them to first-line [status] here will yield better outcomes.”

This is the third FDA approval this year for immunotherapy in endometrial cancer, the doctor noted.

THE 9 MOST COMMON QUESTIONS WOMEN OVER 40 ASK THEIR DOCTORS, ACCORDING TO A MENOPAUSE EXPERT

“This is great news for our patients,” Slomovitz told Fox News Digital.

“Endometrial cancer has become the leading cause of death over all other gynecologic cancers, including ovarian cancer.”

Advertisement

Jemperli (dostarlimab-gxly) — made by British pharmaceutical company GSK — is intended for people who have primary advanced or recurrent forms of the cancer. (iStock)

Before the immunotherapy options became available, the only treatment for endometrial cancer was chemotherapy alone, Slomovitz said. 

“These results are game-changing — it is unprecedented to have three approvals in such a short period of time.”

The most common side effects of all immunotherapy drugs are gastrointestinal, endocrine and dermatologic toxicities, the doctor noted.

“These results are game-changing — it is unprecedented to have three approvals in such a short period of time.”

Advertisement

“Patients should understand that adding immunotherapy to traditional chemotherapy has better results and the toxicity profile is manageable,” he added.

For doctors, Slomovitz emphasized the need to adjust quickly and make the newly approved drug a first-line treatment option for their patients.

GlaxoSmithKline (GSK) is the U.K.-based pharmaceutical company that makes Jemperli. (REUTERS/Dado Ruvic/Illustration/File Photo)

In June, the FDA approved Merck’s Keytruda (pembrolizumab) to be used in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial cancer.

“The Merck trial (pembrolizumab) showed a significant improvement in progression-free survival for all patients,” Slomovitz said.

Advertisement

     

In that same month, AstraZeneca’s Imfinzi (durvalumab) was approved for patients with advanced or recurrent disease who have a certain biomarker.

The AstraZeneca trial also showed improved progression-free survival for all patients. 

All trials for the new cancer drugs were run through the GOG Foundation, which is the largest cooperative group for all gynecologic oncology research, Slomovitz noted. 

“The addition of immunotherapy to chemotherapy provided improvement in survival outcomes without a negative impact on quality of life,” an oncologist said. (iStock)

Advertisement

In the trials, the use of immunotherapy drugs in combination with chemotherapy reduced the risk of disease progression by approximately 70% in patients whose tumors had certain biomarkers.

In other patients without that biomarker, there was still a “clinically and statistically significant improvement in time to progression, which is meaningful for our patients and has now led to FDA approvals in both biomarker settings,” Kathleen N. Moore, M.D., co-director of the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, told Fox News Digital.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“These studies have transformed outcomes for patients with endometrial cancer and are poised to change the treatment landscape for the better into the future,” she added.

Shannon N. Westin, medical director of the Gynecologic Oncology Center at the University of Texas MD Anderson Cancer Center, said she is “thrilled” to have multiple new options for patients with advanced and recurrent endometrial cancer after years with no new therapies.

Advertisement

This is the third FDA approval this year for immunotherapy in endometrial cancer, the doctor noted. “This is great news for our patients,” an oncologist told Fox News Digital. (iStock)

“We no longer have to treat everyone in the same cookie-cutter fashion, and can instead employ precision medicine to improve survival for these survivors.”

For more Health articles, visit www.foxnews/health

“The addition of immunotherapy to chemotherapy provided improvement in survival outcomes without a negative impact on quality of life,” she went on. 

“This is the ideal scenario.”

Advertisement

Fox News Digital reached out to GSK for comment.

Health

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause

Published

on

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause


Advertisement




Melissa Joan Hart Opens up About Weight Loss in Perimenopause | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Alzheimer’s prevention breakthrough found in decades-old seizure drug

Published

on

Alzheimer’s prevention breakthrough found in decades-old seizure drug

NEWYou can now listen to Fox News articles!

A drug that has long been used to treat seizures has shown promise as a potential means of Alzheimer’s prevention, a new study suggests.

The anti-seizure medication, levetiracetam, was first approved by the FDA in November 1999 under the brand name Keppra as a therapy for partial-onset seizures in adults. The approval has since expanded to include children and other types of seizures.

Northwestern University researchers recently found that levetiracetam prevented the formation of toxic amyloid beta peptides, which are small protein fragments in the brain that are commonly seen in Alzheimer’s patients.

The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons, according to the study findings, which were published in Science Translational Medicine.

Advertisement

The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease.

The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons. (iStock)

“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid‑beta 42 peptides and amyloid plaques,” said corresponding author Jeffrey Savas, associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine, in a press release. 

“Our new results uncovered new biology while also opening doors for new drug targets.”

HIDDEN BRAIN CONDITION MAY QUADRUPLE DEMENTIA RISK IN OLDER ADULTS, STUDY SUGGESTS

Advertisement

The brain is better able to avoid the pathway that produces toxic amyloid‑beta 42 proteins in younger years, but the aging process gradually weakens that ability, Savas noted. 

“This is not a statement of disease; this is just a part of aging. But in brains developing Alzheimer’s, too many neurons go astray, and that’s when you get amyloid-beta 42 production,” he said. 

The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease. (iStock)

That then leads to tau (“tangles”) — abnormal clumps of protein inside brain neurons — which can kill brain cells, trigger neuroinflammation and lead to dementia.

In order for levetiracetam to function as an Alzheimer’s blocker, high-risk patients would have to start taking it “very, very early,” Savas said — up to 20 years before elevated amyloid-beta 42 levels would be detected.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death,” the researcher noted.

The researchers also did a deep dive into previous human clinical data to determine whether Alzheimer’s patients who were taking the anti-seizure drug had slower cognitive decline. They reported that the patients in that category had a “significant delay” in the span from cognitive decline to death compared to those not taking the drug.

“This analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” the researcher said. (iStock)

“Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” Savas said.

Advertisement

Looking ahead, the research team aims to find people who have genetic forms of Alzheimer’s to participate in testing, Savas said.

Limitations and caveats

The study had several limitations, including that it relied on animal models and cultured cells, with no human trials conducted.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Because the study was observational in nature, it can’t prove that the medication caused the prevention of the toxic brain proteins, the researchers acknowledged.

Savas noted that levetiracetam “is not perfect,” cautioning that it breaks down in the body very quickly.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The team is currently working to create a “better version” that would last longer in the body and “better target the mechanism that prevents the production of the plaques.”

“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death.”

The medication’s common documented side effects include drowsiness, weakness, dizziness, irritability, headache, loss of appetite and nasal congestion.

It has also been linked to potential mood and behavior changes, including anxiety, depression, agitation and aggression, according to the prescribing information. In rare cases, it could lead to severe allergic reactions, skin reactions, blood disorders and suicidal ideation.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Funding for the study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund.

Fox News Digital reached out to the drug manufacturer and the researchers for comment.

Related Article

Alzheimer’s decline could slow dramatically with one simple daily habit, study finds
Continue Reading

Health

Seniors over 80 who eat specific diet may be less likely to reach 100 years old

Published

on

Seniors over 80 who eat specific diet may be less likely to reach 100 years old

NEWYou can now listen to Fox News articles!

Older adults who avoid meat in their golden years may be less likely to reach age 100 than their meat-eating counterparts, new research suggests.

Researchers tracked more than 5,000 adults aged 80 or older who were enrolled in the Chinese Longitudinal Healthy Longevity Survey.

Between 1998 and 2018, data showed that those who did not eat meat were less likely to reach their 100th birthday than those who consumed animal products regularly.

The findings seem to contradict previous studies that have linked vegetarianism and plant-based diets to lower risks of heart disease, stroke, diabetes and obesity.

Advertisement

Most evidence supporting the benefits of plant-based diets comes from studies tracking younger populations, the researchers noted. 

The findings contrast with previous research praising plant-based diets for their positive influence on heart health. (iStock)

The study, published in The American Journal of Clinical Nutrition, points to losses in muscle mass and bone density with age, shifts that can increase the risk of malnutrition and frailty in the “oldest old.”

As people enter their 80s and 90s, the nutritional priority often shifts from preventing long-term chronic diseases to maintaining day-to-day physical function, experts say.

HOW MUCH RED MEAT IS TOO MUCH? EXPERTS WEIGH IN ON FOOD PYRAMID UPDATES

Advertisement

“The headline ‘vegetarians over 80 less likely to reach 100’ sounds surprising, because it contrasts with decades of data linking plant‑forward diets to lower chronic disease risk earlier in life,” Erin Palinski-Wade, a New Jersey-based registered dietitian, told Fox News Digital. 

“However, once you see that this research is limited to adults over the age of 80 who are also underweight — and that this link disappears with the consumption of eggs, dairy and fish — the results are less surprising.”

While diets earlier in life tend to emphasize avoiding long-term disease, older age necessitates nutrients and weight maintenance, experts say. (iStock)

In those over 80, restricting animal proteins may be less likely to promote longevity, according to Palinski-Wade, who was not involved in the study.

Eliminating all animal protein — particularly in a population that may already experience diminished hunger cues — can make it more difficult to meet adequate protein needs, potentially increasing the risk of nutrient deficiencies, the nutritionist said.

Advertisement

ALZHEIMER’S SYMPTOMS COULD BE PREDICTED YEARS IN ADVANCE THROUGH ONE SIMPLE TEST

In addition to a higher tendency to be underweight, older populations also face a greater risk of bone fractures due to lower calcium and protein intake.

Potential limitations

The lower rate of vegetarians reaching 100 was only observed in participants identified as underweight, the researchers noted. No such association was found in people who maintained a healthy weight.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Because being underweight is already linked to greater frailty and mortality risk, the researchers noted that body weight may partly explain the findings, making it difficult to determine whether diet itself played a direct role.

Advertisement

Those incorporating animal-sourced products other than meat were just as likely to live to 100. (iStock)

Additionally, the shortened lifespans were not found in people who continued to eat non-meat animal products, such as fish, dairy and eggs. 

Older adults with these more flexible diets were just as likely to live to 100 as those eating meat, as these foods may provide the nutrients necessary for maintaining muscle and bone health, the researchers noted.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“This is an observational study, so it can only show associations, and does not prove that avoiding meat directly reduces the odds of reaching 100,” Palinski-Wade added.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

The researchers suggested that including small amounts of animal-sourced foods could help older seniors maintain essential nutrients and avoid the muscle loss often seen in those who stick strictly to plants.

Eliminating all animal protein — particularly in a population that may already experience diminished hunger cues — can make it more difficult to meet adequate protein needs, potentially increasing the risk of nutrient deficiencies. (iStock)

Palinski-Wade offered some guidance for those looking to optimize nutrition later in life.

“For adults in their 80s and beyond, especially anyone losing weight or muscle, the priority should be maintaining a healthy weight and meeting protein and micronutrient needs — even if that means adding or increasing fish, eggs, dairy or well‑planned, fortified plant proteins and supplements.”

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Strict vegan or very low‑protein patterns at that age should be carefully monitored by a dietitian or clinician, with attention to B12, vitamin D, calcium and total protein, according to Palinski-Wade.

“Younger and healthier adults can still confidently use plant‑forward or vegetarian patterns to lower long‑term chronic disease risk,” she added.

Related Article

Scientists reveal the one practice that could prevent dementia as you age
Continue Reading

Trending